Overview

A Safety and Efficacy Study of Xolair in Peanut Allergy

Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Omalizumab